Evidence types
Clinical study articles covering observational research, trial reports, and human data relevant to Crohn's disease and IBD.
Page 19 of 21 · 1007 articles
The study synthesizes many stool metagenomes to find consistent microbial species, functional pathways, and strain-level differences linked to IBD and to distinctions between Crohn’s disease and ulcerative...
If you have ulcerative colitis, the study suggests that TCM pattern labels (DCSR vs PXSY) align with measurable differences in inflammation and tissue damage, which could influence personalized symptom assessment or...
Gut microbes produce small molecules that interact with the host. This study shows lower levels of certain microbial aromatic carboxaldehydes (I3A and 4HBA) in feces from people with Crohn’s disease, suggesting a...
CMV reactivation can worsen outcomes in active UC and influence treatment choices; clinicians and patients may benefit from additional, easy-to-measure markers that flag higher risk of tissue CMV and prompt targeted...
A blood biomarker that rises with active ulcerative colitis could help patients and clinicians monitor disease activity without relying solely on invasive tests. This study reports that serum type 23 collagen ectodomain...
This large, population-based study suggests people with Crohn's disease have modestly higher overall mortality than matched controls and higher deaths from specific causes (colorectal cancer, renal disease, non-Hodgkin...
The study suggests that while Crohn's disease produces a shared dysbiotic signature at diagnosis, the specific microbes enriched differ by age — notably oral-associated taxa in children — which could affect research into...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
If validated, the study points to a specific neutrophil subset that may drive inflammation and barrier damage in IBD, and to CXCR4 as a possible therapeutic target. That could open new biology-based treatment approaches...
Researchers used genetics, microbiome, metabolism, and immune profiling together to nominate biological pathways and a four-gene signature that might help diagnose or explain ulcerative colitis. If validated later, these...
If validated, a blood biomarker (LRG) could help predict which people with Crohn’s disease are more likely to achieve remission and which biologic might be sustained over a year, informing treatment planning and...
People with UC have higher rates of low bone density, which raises fracture risk. This study links altered hormones (leptin, ghrelin, IGF‑1) and inflammation to lower BMD in UC, suggesting metabolic pathways that could...
This study suggests that higher intake of specific fibers (beta‑glucan and inulin) may be linked to lower Crohn’s risk in people with a family history, and it connects those fibers to biomarkers of inflammation, barrier...
Vitamin D supplementation is commonly considered in people with IBD because deficiency is frequent and low vitamin D may relate to inflammation.
The work identifies a genetic link (HLA‑DRB1*01:03) to anti‑IL‑10 autoantibodies and describes a small subgroup of IBD patients who may have a distinct immune mechanism driving disease—information that could matter for...
The gut microbiome differed more in pediatric Crohn’s disease and acute pancreatitis than in IBS or healthy kids, suggesting microbial changes are stronger in organic inflammatory disease and could be targets for future...
If confirmed, a simple blood marker (NLR) plus biopsy results could help identify UC patients at higher risk of relapse despite endoscopic improvement, which might guide monitoring or treatment choices.
Cure8 found this source from Gastroenterology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Research and clinical trials. Open the original article for the full details.
Identifies features associated with the new international definition of difficult‑to‑treat Crohn’s disease and links DTT status to greater mental fatigue. Biomarker differences (IL‑5, IL‑10) may point to distinct immune...
Fatigue affects many people with Crohn’s even when inflammation looks controlled; recognizing it as a distinct target could change clinic assessments and treatment priorities.
Patients with small-bowel strictures face repeat procedures or surgery; this study suggests endoscopic stricturotomy outcomes differ by whether the stricture is from Crohn’s disease and that a simple blood marker (NLR)...
The study suggests that being symptom-free doesn’t guarantee the gut’s microbiome, metabolome, or epithelial functions have returned to a healthy state. Diet—especially ultraprocessed-food intake—was linked to persistent...
If hospital-treated infections raise later IBD risk—especially in people with certain immune-related genetic variants—this supports a multi-hit model of IBD and could eventually help identify higher-risk individuals...
The study suggests upadacitinib may improve both symptoms and MRI‑documented healing of perianal fistulas in Crohn’s disease, offering a potential treatment option especially for patients who have not previously received...
Postoperative recurrence after ileal resection is common in Crohn’s disease; understanding microbial changes linked to recurrence could help explain mechanisms and guide future biomarker development.
The project could reveal a new neuro-immune circuit (IL-17A acting on enteric neurons) that promotes tissue protection during intestinal inflammation, suggesting novel non-immunosuppressive therapeutic targets for IBD.
People with longstanding ulcerative colitis face higher colorectal cancer risk; this project focuses on a specific immune/stromal cell population (ST2+ cells responding to IL-33) that may help explain how chronic...
This project studies a novel enzyme target (GCPII) that is reportedly upregulated in IBD and may change glutamate signaling and barrier function; understanding it could point to new treatment strategies for people whose...
Intestinal fibrosis and strictures remain a major cause of surgery and obstruction in Crohn’s disease, and current anti-inflammatory drugs don’t reliably prevent fibrosis. If microbial choline degradation promotes...
The study could create a human-derived lab model to better understand and treat colitis caused by cancer immunotherapy, and to evaluate IBD drugs for that purpose without compromising tumor control.
Researchers are exploring plant-derived polysaccharides as potential therapies that might reduce inflammation and protect the intestinal barrier. For people with UC, therapies that reduce pyroptosis and restore...
Small-bowel Crohn's disease often causes strictures and fistulas and typically needs more imaging and procedural care than colonic disease, so patients and clinicians should be aware of its distinct risks and treatment...
The study suggests measurable retinal and choroidal microvascular differences in people with IBD versus controls, which could point to systemic vascular effects of inflammation and offer noninvasive biomarker...
Intestinal fibrosis causes strictures that can lead to obstruction and often require surgery; current drugs mainly reduce inflammation and do not reliably prevent or reverse fibrosis. Advances in understanding fibrosis...
The study identifies a sizable group of patients in Latin America with difficult-to-treat IBD—especially Crohn’s disease—highlighting higher disease severity, younger onset, and longer diagnostic delays that can affect...
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.
This study suggests a traditional processing method may change a common herbal used for UC so it works better in mouse and cell models, and it proposes a specific molecular pathway (LCN2‑mediated pyroptosis) that could...
AI tools like Google NotebookLM could make systematic reviews and consensus statement processes faster and less labor-intensive for IBD-related evidence, while maintaining very low rates of major factual errors.
If validated, a blood test for cytotoxic CD4+ T cells at diagnosis could help predict who is less likely to respond to anti‑TNF drugs, potentially allowing earlier selection of alternative therapies for some children...
Genetic primary bile acid malabsorption can produce IBD-like symptoms and may be missed in children labeled with Crohn's disease; recognizing PBAM could change testing and management for some patients.
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Aminosalicylates. The original article is from Digestive Diseases and Sciences.
Many people with Crohn's also have obesity or diabetes and may be prescribed GLP-1 drugs. Understanding safety, symptom overlap, and current research helps you and your care team make informed choices about starting or...
This study suggests a targeted phage can reduce inflammation driven by Crohn’s‑associated E. coli without wiping out the gut microbiome, and it may boost the effect of lower steroid doses. That could eventually mean...
This study suggests a new, targeted way to reduce gut inflammation by disabling harmful E. coli behaviors linked to Crohn's disease without wiping out the microbiome.
Cure8 found this source from academic.oup.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Crohn's disease, and Research and clinical trials. Open the original article for...
The study pinpoints a genetic cause (BIRC3 variants) that disrupts a TNF/RIPK1 immune pathway linked to Crohn’s disease, suggesting a targetable mechanism. That could help doctors match patients to treatments and guide...
Cure8 found this source from iovs.arvojournals.org, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Biomarker. Open the original article for the full...
Scientists found BIRC3 gene changes that cause Crohn’s in some patients and showed those changes drive inflammation through the RIPK1/TNF pathway. That suggests a new, druggable pathway and may help predict who benefits...
